Natural Products Insider is part of the Informa Markets Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
HomeBusiness ResourcesBusiness OperationsLabs/TestingChromaDex Announces Top Line Results of its Second Human Clinical Trial

ChromaDex Announces Top Line Results of its Second Human Clinical Trial

<p>ChromaDex Corp. (NASDAQ:CDXC announced today that the initial results of its second human clinical study of NIAGEN<sup>&reg;</sup> nicotinamide riboside chloride (NR) have confirmed NR significantly and sustainably raises the co-enzyme nicotinamide adenine dinucleotide (NAD+) in 140 healthy human volunteers over 8-weeks.</p>
TAGS: Healthy Living Ingredients Business Resources
Hide comments
account-default-image
user not logged in

More information about text formats

Comments

  • Allowed HTML tags: <em> <strong> <blockquote> <br> <p>

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Publish
Related
CBD oil containers
Undisclosed THC threatens CBD market
Aug 04, 2022
U.S. Hemp Authority Seal
Hemp quality standards cut delta-8 THC from consideration
Jun 05, 2022
Creatine Whey and BCAAs
Protein shenanigans: Spiking, shortcutting quality and source mixing
May 10, 2022
Greed in the supplement market
Rumblings, musings on supply chain woes, greed in dietary supplements
May 10, 2022